Evidence map›Paper›PMID 39480108›Full record

ReviewmBio2024

Emerging mosquito-borne flaviviruses.

Amy N Nelson, Alexander Ploss

Abstract readReview
In one paragraph

Review in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. The inhibition mechanism ofFrontiers in microbiology · 2026
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amy N NelsonDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.ORCID 0000-0002-3654-163X
Alexander PlossDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, USA.ORCID 0000-0001-9322-7252

Funding

PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007388 · NIGMS · PRINCETON UNIVERSITY · PI CRISTEA, ILEANA M. · 1985 to 2022
$27.4M
Rational design and efficacy testing of vaccines against HCVR01AI168048 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Alexander Andrianov, Thomas R Fuerst · 2022 to 2026
$7.1M
Genetic Viral and Host Adaptations to Breach Species Barriers of HCVR01AI107301 · NIAID · PRINCETON UNIVERSITY · PI Thomas Pietschmann, Alexander Ploss · 2013 to 2026
$6.0M
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infectionR01AI138797 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PLOSS, ALEXANDER, SU, LISHAN · 2018 to 2022
$3.9M
Methods and Logic in Molecular Biology Training ProgramT32GM148739 · NIGMS · PRINCETON UNIVERSITY · PI Ileana M. Cristea · 2023 to 2026
$3.6M
Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment ResponseR01AI146917 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI DAHARI, HAREL · 2020 to 2024
$3.5M
Targeting hepatitis B virus cccDNA during HBV/HIV co-infectionR01AI181664 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2024 to 2025
$3.0M
Mechanisms of hepatitis B virus cccDNA formationR01AI153236 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2020 to 2024
$2.8M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01 AI138797, R01 AI153236, R01 AI146917, R01 AI168048, R01 AI107301, R01AI181664, U19A171401HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007388, T32GM148739NIAID NIH HHS R01 AI107301NIAID NIH HHS R01 AI138797NIAID NIH HHS R01 AI146917NIAID NIH HHS R01 AI153236NIAID NIH HHS R01 AI168048NIAID NIH HHS R01 AI181664NIGMS NIH HHS T32 GM007388NIGMS NIH HHS T32 GM148739Princeton University (PU)
6 · The paper itself

Abstract

Flaviviruses comprise a genus of enveloped, positive-sense, single-stranded RNA viruses typically transmitted between susceptible and permissive hosts by arthropod vectors. Established flavivirus threats include dengue viruses (DENV), yellow fever virus (YFV), Zika virus (ZIKV), and West Nile virus (WNV), which continue to cause over 400 million infections annually and are significant global health and economic burdens. Additionally, numerous closely related but largely understudied viruses circulate in animals and can conceivably emerge in human populations. Previous flaviviruses that were recognized to have this potential include ZIKV and WNV, which only became extensively studied after causing major outbreaks in humans. More than 50 species exist within the flavivirus genus, which can be further classified as mosquito-borne, tick-borne, insect-specific, or with no known vector. Historically, many of these flaviviruses originated in Africa and have mainly affected tropical and subtropical regions due to the ecological niche of mosquitoes. However, climate change, as well as vector and host migration, has contributed to geographical expansion, thereby posing a potential risk to global populations. For the purposes of this minireview, we focus on the mosquito-borne subgroup and highlight viruses that cause significant pathology or lethality in at least one animal species and/or have demonstrated an ability to infect humans. We discuss current knowledge of these viruses, existing animal models to study their pathogenesis, and potential future directions. Emerging viruses discussed include Usutu virus (USUV), Wesselsbron virus (WSLV), Spondweni virus (SPOV), Ilheus virus (ILHV), Rocio virus (ROCV), Murray Valley encephalitis virus (MVEV), and Alfuy virus (ALFV).

Indexed as

CulicidaeFlavivirusFlavivirus InfectionsMosquito VectorsAnimalsCommunicable Diseases, EmergingHumansantiviral immunityemerging virusesflavivirusinfectious diseasespecies tropism

Identifiers

PMID39480108
PMCPMC11633211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.